Vanadium Compounds: Biochemical and Therapeutic Applications

Front Matter....Pages i-1
Front Matter....Pages 3-3
The chemistry of peroxovanadium compounds relevant to insulin mimesis....Pages 5-15
Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents....Pages 17-24
Peroxo heteroligand vanadates(V): Synthesis, spectra-structure relationships, and stability toward decomposition....Pages 25-29
Chemically and photochemically initiated DNA cleavage by an insulin-mimetic bis peroxovanadium complex....Pages 31-36
Front Matter....Pages 37-37
Insulin-like actions of vanadate are mediated in an insulin-receptor-independent manner via non-receptor protein tyrosine kinases and protein phosphotyrosine phosphatases....Pages 39-47
Peroxovanadium compounds: Biological actions and mechanism of insulin-mimesis....Pages 49-58
Unique and selective mitogenic effects of vanadate on SV40-transformed cells....Pages 59-67
Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases....Pages 69-78
Protective effect of vanadate on oxyradical-induced changes in isolated perfused heart....Pages 79-85
 In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals....Pages 87-94
The relationship between insulin and vanadium metabolism in insulin target tissues....Pages 95-102
Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling....Pages 103-112
Reversal of defective G-proteins and adenylyl cyclase/cAMP signal transduction in diabetic rats by vanadyl sulphate therapy....Pages 113-119
Effects of vanadate on the expression of genes involved in fuel homeostasis in animal models of Type I and Type II diabetes....Pages 121-124
Decrease in protein tyrosine phosphatase activities in vanadate-treated obese Zucker (fa/fa) rat liver....Pages 125-129
Evidence for selective effects of vanadium on adipose cell metabolism involving actions on cAMP-dependent protein kinase....Pages 131-137
The enhancement by pervanadate of tyrosine phosphorylation on prostatic proteins occurs through the inhibition of membrane-associated tyrosine phosphatases....Pages 139-144
Contractile effects of vanadate on aorta rings from virgin and pregnant rats....Pages 145-150
 In vivo modulation of N-myristoyltransferase activity by orthovanadate....Pages 151-155
Regulation and control of glucose overutilization in erythrocytes by vanadate....Pages 157-160
Front Matter....Pages 37-37
 In vitro and in vivo antineoplastic effects of ortrovanadate....Pages 161-166
Membrane — vanadium interaction: A toxicokinetic evaluation....Pages 167-171
Front Matter....Pages 173-173
Increased potency of vanadium using organic ligands....Pages 175-180
 In vivo effects of peroxovanadium compounds in BB rats....Pages 181-190
Long-term antidiabetic activity of vanadyl after treatment withdrawal: Restoration of insulin secretion?....Pages 191-195
Long-term correction of STZ-diabetic rats after short-term i.p. VOSO 4 treatment: Persistence of insulin secreting capacities assessed by isolated pancreas studies....Pages 197-204
Antihypertensive effects of vanadium compounds in hyperinsulinemic, hypertensive rats....Pages 205-209
Vanadate induces normolipidemia and a reduction in the levels of hepatic lipogenic enzymes in obese Zucker rat....Pages 211-215
 In vivo and in vitro studies of vanadate in human and rodent diabetes mellitus....Pages 217-231
Toxicology of vanadium compounds in diabetic rats: The action of chelating agents on vanadium accumulation....Pages 233-240
Back Matter....Pages 241-244